Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC-MS/MS and its application to pharmacokinetic study in clinic.
A new high-throughput LC-MS/MS method for the simultaneous determination of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in human plasma is presented, with zidovudine as an internal standard. The analytes were extracted from plasma by protein precipitation and only 150 microL plasma was needed. Chromatographic separation was achieved on a Shiseido C(8) column (150 x 2.0 mm, 5 microm) with a total run time of 6 min. A tandem mass spectrometric detection was conducted using multiple reaction monitoring under positive ionization mode with an electrospray ionization interface. The method was developed and validated over the concentration range of 25-5000 ng/mL for 3TC and NVP and 20-4000 ng/mL for d4T. The method was validated in terms of intra- and inter-day precision (< or = 8.6%), accuracy (within +/- 8.4%), linearity and specificity. The method has been successfully applied to the pharmacokinetic study of a combination treatment of 300 mg lamivudine, 30 mg stavudine and 200 mg nevirapine in 22 healthy male volunteers under fasting conditions.
Li
Zhou
Z
Shanghai Institute of Pharmaceutical Industry, National Pharmaceutical Engineering and Research Center, People's Republic of China.
Ding
Cungang
C
Ge
Qinghua
Q
Zhou
Zhen
Z
Zhi
Xiaojin
X
Liu
Xiaofen
X
D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D019259:Lamivudine / Q000097:blood* / Q000493:pharmacokinetics*; D008297:Male; D019829:Nevirapine / Q000097:blood* / Q000493:pharmacokinetics*; D018119:Stavudine / Q000097:blood* / Q000493:pharmacokinetics*; D053719:Tandem Mass Spectrometry / Q000379:methods*
D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine